Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease
Authors not listed
University of California, Davis · 2022
Abstract
Development of novel disease-modifying therapies for Alzheimer's disease (AD) remains of paramount importance. This study will be a Phase II randomized clinical trial testing Senicapoc in patients with mild or prodromal AD. This will be a small Proof of Mechanism study to prove biological activity and target engagement in humans with early AD. The investigators will study up to 55 patients over 52 weeks, with primary outcomes being Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS-Cog) scores and blood and cerebrospinal fluid (CSF) markers of neuroinflammation. This pilot study will provide an estimate of treatment effect size on cognitive trajectory, daily function, and brain atrophy.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Anonymous. (2022). Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease. <em>University of California, Davis</em>. https://clinicaltrials.gov/study/NCT04804241
Vancouver
Anonymous. Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease. University of California, Davis. 2022.
BibTeX
@misc{anon2022Proofo,
title = {Proof of Mechanism Study of Senicapoc in Mild or Prodromal Alzheimer's Disease},
author = {Anonymous},
journal = {University of California, Davis},
year = {2022},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Poitiers University Hospital 2023
Open access · US-GOV
Pilot Study on the Feasibility of Using Smartphone Data as a Diagnostic Marker for Alzheimer's Disease
University Hospital, Strasbourg, France 2012
Open access · US-GOV
Evaluation of fMRI-SAM in the Early Detection of Alzheimer's Disease.
Aleksandra Stark 2017
Open access · US-GOV
A Phase IIa Proof of Concept, Randomized, Double-blind, Placebo-controlled Study of the Effects of L-serine on Early Stage Alzheimer's Disease Patients
Medical College of Wisconsin 2009
Open access · US-GOV
A Composite MR Neuroimaging Marker for Alzheimer's Disease
University Hospital, Montpellier 2021
Open access · US-GOV
Analysis of the Blood Signature of the Microbiota as a Diagnostic Marker of Alzheimer's Disease in the Early Stages of the Process: Pilot Study
Federico II University 2022
Open access · US-GOV